(Q38041481)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

amyotrophic lateral sclerosis

12 February 2020

main subject

0 references

author

Yan Jouroukhin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Regina Ostritsky

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Illana Gozes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

Journal of Molecular Neuroscience

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

597-602

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22956189%20AND%20SRC:MED&resulttype=core&format=json

Association of an extended haplotype in the tau gene with progressive supranuclear palsy

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

ALS: a disease of motor neurons and their nonneuronal neighbors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Tau alteration and neuronal degeneration in tauopathies: mechanisms and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

A femtomolar-acting neuroprotective peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Protective peptides that are orally active and mechanistically nonchiral

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Peptide-mediated protection from ethanol-induced neural tube defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

First tau repeat domain binding to growing and taxol-stabilized microtubules, and serine 262 residue phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Peptide neuroprotection through specific interaction with brain tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Altered levels and distribution of microtubule-associated proteins before disease onset in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Tau Pathology and Future Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Expression of peripherin in ubiquinated inclusions of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Tau and caspase 3 as targets for neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Prevention of learning deficit in a Down syndrome model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Molecular biology of amyotrophic lateral sclerosis: insights from genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Ethanol antagonist peptides: structural specificity without stereospecificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Tubulin requires tau for growth onto microtubule initiating sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-012-9882-6

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

21 January 2018

1 reference

12 December 2020

Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides

1 reference

12 December 2020

NAP protects against cyanide-related microtubule destruction

1 reference

12 December 2020

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

1 reference

12 December 2020

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis

1 reference

12 December 2020

Pathogenesis of the tauopathies

1 reference

12 December 2020

Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer's disease and Pick's disease

1 reference

12 December 2020